A-423,579
From Self-sufficiency
| A-423,579 | |
|---|---|
| File:A-423,579 structure.png | |
| 4-(4-{3-[3-(dimethylamino)pyrrolidin-1-yl]propoxy}-3,5-difluorophenyl)benzonitrile | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 461045-17-0 |
| PubChem | 11349657 (3R)  , 22994515
|
| ChemSpider | 9524593 (3R)
|
| ChEBI | 601582 |
| SMILES | Script error: No such module "collapsible list". |
| InChI | Script error: No such module "collapsible list". |
| InChI key | DJXFZKXYKKBTDR-UHFFFAOYSA-N |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C22H25F2N3O |
| Molar mass | 385.45 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
A-423,579 is one of a range of histamine antagonists developed by Abbott Laboratories which are selective for the H3 subtype, and have stimulant and anorectic effects in animal studies making them potentially useful treatments for obesity. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.[1][2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 45px | This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. |
